@article{31aa2cbc1c5d417692ed081050a02c49,
title = "Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using 18F-FDG PET/MRI",
keywords = "CANAGLIFLOZIN, DAPAGLIFLOZIN, DOUBLE-BLIND, EFFICACY, EMPAGLIFLOZIN, GLUCOSE, IMPROVES GLYCEMIC CONTROL, PET (positive emission tomography), SAFETY, SPLIT RENAL-FUNCTION, TRANSIT-TIME, renal function, sodium glucose cotransporter, type 2 diabetes",
author = "Sazan Rasul and Geist, {Barbara Katharina} and Helmut Brath and Pascal Baltzer and Sundar, {Lalith Kumar Shiyam} and Verena Pichler and Markus Mitterhauser and Alexandra Kautzky-Willer and Marcus Hacker",
note = "Publisher Copyright: {\textcopyright} {\textcopyright} Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2020",
month = mar,
doi = "10.1136/bmjdrc-2019-001135",
language = "English",
volume = "8",
journal = "BMJ open diabetes research & care",
issn = "2052-4897",
publisher = "BMJ PUBLISHING GROUP",
number = "1",
}
